• Subcutaneous continuous glucose monitoring and intravenous dosing of insulin and dextrose for automated glycemic control in the inpatient setting
Do you have Type 2 Diabetes?
Do you use at least 40 units of NPH insulin a day?
Do you want to participate in cutting edge research?

If so you may be eligible for a research study at Mass General Hospital, designed to test an experimental device that will control blood sugar automatically.

This research study involves two visits lasting 1 hour or less, and one 12 hour visit in the hospital, during which you will have 2 IV catheters placed in your arms. Compensation is provided: $350 if you complete all three visits.

If you are interested please contact Rachel Kochis, RN at 617-724-0112 or via email rkochis@partners.org.
Institution  –  MGH - Massachusetts General Hospital, Boston, MA
Principal Investigator  – Steven J Russell, MD, PhD
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name  – Kerry B Grennan, NP
Email  – kgrennan@partners.org
Phone  – 617-724-7700

About Type 1 Diabetes:
Type 1 diabetes accounts for 5 to 10 percent of all diagnosed cases of diabetes in the US. Type 1 diabetes usually develops in children or young adults, but can start at any age. It may also be known by a variety of other names, including the following:
  • insulin-dependent diabetes mellitus (IDDM)
  • juvenile diabetes
  • brittle diabetes
  • sugar diabetes
There are two forms of type 1 diabetes:
  • idiopathic type 1 diabetes - refers to rare forms of the disease with no known cause.
  • immune-mediated diabetes - an autoimmune disorder in which the body's immune system destroys, or attempts to destroy, the cells in the pancreas that produce insulin. Immune-mediated diabetes is the most common form of type 1 diabetes, and the one generally referred to as type 1 diabetes. The information on this page refers to this form of type 1 diabetes.